Advanced searches left 3/3

Alpelisib - DOAJ

Summarized by Plex Scholar
Last Updated: 03 July 2022

* If you want to update the article please login/register

S.U.G.A.R: A Case to Outline Tactics for the Prevention of Alpelisib-Induced Hyperglycemia

Metastatic breast cancer patients with minimal toxicities may live years with their disease on drugs with minimal toxicities for years, but they will eventually progress on first-line therapy. In estrogen receptoru2013positive, her2-negative disease, PIK3CA mutation testing is recommended for those eligible for second-line therapy. Hyperglycemia is a common side effect of alpharemia. We discuss a case of diabetic ketoacidosis necessitating intervention in the intensive care unit of a woman with type 2 diabetes mellitus who started on alisib. Since progress on first-line therapy, a 76-year-old female with diet-controlled T2DM and mBC was put on second-line therapy with alchib. We have five recommendations to avoid hyperglycemia in those on apelisib: stringent guidelines for starting alglycemia, comprehend the steps required to prevent hyperglycemia, aid a multidisciplinary team, take action immediately if hyperglycemia is identified, and log blood glucose levels.

Source link: https://doi.org/10.1177/23247096221105249

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions